GRAIL secures FDA breakthrough device designation for multi-cancer test

Image: GRAIL has previously reported data from the first pre-planned sub-study of its Circulating Cell-free Genome Atlas (CCGA) study. Photo courtesy of allinonemovie from Pixabay.